Investors & Media

PRESS RELEASE


<< Back
Flex Pharma to Report First Quarter 2018 Financial Results on May 2, 2018

BOSTON--(BUSINESS WIRE)--Apr. 25, 2018-- Flex Pharma, Inc. (NASDAQ: FLKS), a clinical-stage biotechnology company that is developing innovative and proprietary treatments for cramps and spasticity associated with severe neurological diseases such as multiple sclerosis (MS), Charcot-Marie-Tooth (CMT) and amyotrophic lateral sclerosis (ALS) under FDA Fast Track designation, announced today that it will report its financial results for the first quarter ended March 31, 2018 on Wednesday, May 2, 2018 before the U.S. financial markets open. The Company will host a conference call and webcast at 9:00 a.m. ET to discuss first quarter 2018 financial results and provide a business update. Individuals interested in participating in the call should dial (855) 780-7202 (U.S. and Canada) or (631) 485-4874 (International).

A live webcast may be accessed in the Investors & Media section of the Company's website at www.flex-pharma.com. Please log on to the Flex Pharma website approximately 15 minutes prior to the scheduled webcast to ensure adequate time for any software downloads that may be required. A replay of the webcast will be available on Flex Pharma's website for 90 days following the event.

About Flex Pharma

Flex Pharma, Inc. is a clinical-stage biotechnology company that is developing innovative and proprietary treatments in Phase 2 randomized, controlled trials for cramps and spasticity associated with the severe neurological diseases of ALS, MS and peripheral neuropathies such as Charcot-Marie-Tooth (CMT). The Company’s lead candidate, FLX-787, is being developed under Fast Track designation for the treatment of severe muscle cramps associated with ALS. Flex Pharma was founded by National Academy of Science members Rod MacKinnon, M.D. (2003 Nobel Laureate), and Bruce Bean, Ph.D., recognized leaders in the fields of ion channels and neurobiology, along with Christoph Westphal, M.D., Ph.D.

Click to Tweet this News

Source: Flex Pharma, Inc.

Flex Pharma, Inc.
Elizabeth Woo, 617-874-1829
SVP, Investor Relations & Corporate Communications
irdept@flex-pharma.com